Tuesday, July 10, 2012

Bristol Myers and Ono Pharmaceuticals file SC Orencia for Approval in Japan

BMY and ONO have filed an approval application for SC version of Orencia to MHLW.  ORENCIA IV  was launched in September 2010 in Japan where it is indicated for use of rheumatoid arthritis only for patients with an inadequate response to prior conventional therapy.(DMARD).
On September 21, 2011, ONO and BMY  entered into a collaboration agreement for ORENCIA®. The companies will co-promote ORENCIA 250mg Intravenous Injection, which BMY has been distributing since September 2010, and also this Subcutaneous Injection, if approved, for which the new application was filed